Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr ! (Seite 606)

[Durim02]

Antwort auf Beitrag Nr.: 66.809.764 von Christian1279 am 04.02.21 04:47:47

Kannst du es bitte erläutern?

[Christian1279]

Antwort auf Beitrag Nr.: 66.809.440 von ben1984 am 04.02.21 00:40:56

Hast du überhaupt den Sinn dahinter verstanden?! Ich denke nicht bei dem Quatsch den du da so schreibst!!

[ben1984]

WTF

Warum zu dem Kurs?
Warum nicht höher?

Wer hat denn da geschlafen

Was ein scheiss timing

Gute Nacht - genug für heute

[MStorm]

LONDON, ON, Feb. 3, 2021 /CNW/ - Sernova Corp. ("Sernova" or the "Company") (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc., as the co-lead underwriters (together, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 8,350,000 units of the Company (the "Units") at a price of C$1.20 per Unit (the "Issue Price") for gross proceeds to the Company of approximately C$10,020,000 (the "Offering").

Each Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of $1.70 (the "Exercise Price") at any time up to 24 months following Closing Date (as defined below). The expiry date of the Warrants may be accelerated by the Company at any time if the volume weighted average price of the Common Shares on the TSX Venture Exchange (the "Exchange") is greater than $3.05 for any ten (10) consecutive trading days, at which time the Company may accelerate the expiry date of the Warrants by providing notice to holders of Warrants, whereupon the Warrants will expire not less than 30 days after the date of such notice.

The Company has granted the Underwriters an option (the "Over-Allotment Option"), exercisable in part or in whole at the Underwriters' discretion, at any time until thirty (30) days following the Closing Date, to purchase up to the number of additional Units equal to 15% of the aggregate number of Units sold in the Offering to cover over-allotments, if any.

The Offering will be completed (i) by way of a short form prospectus to be filed in those provinces of Canada other than Quebec as the Underwriters and the Company may designate pursuant to National Instrument 44-101 – Short Form Prospectus Distributions, (ii) on a private placement basis in the United States pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and applicable U.S. state securities laws, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company's securities under domestic or foreign securities laws.

The net proceeds of the Offering will be used to advance the Company's clinical development program, including its US Phase I/II Cell Pouch clinical trial, expand Sernova's research and development programs, including our local immune protection technologies for the Cell Pouch, as well as for working capital and general corporate purposes.

The Underwriters shall be paid (i) a commission (the "Cash Commission") equal to 6.5% of the aggregate gross proceeds of the Offering payable in cash or Units, or any combination thereof, at the option of the Underwriters and (ii) warrants (the "Underwriters' Warrants") exercisable at any time up to 24 months following Closing Date to acquire the number of Units equal to 6.5% of the aggregate number of Units issued pursuant to the Offering, at an exercise price equal to the Issue Price, other than up to C$500,000 of Units subscribed for by investors introduced to the Offering by the Company, in which case both the Cash Commission and the Underwriters' Warrants will be reduced to 2.0%. Additionally, the Company shall pay the Underwriter's a corporate finance fee payable in Units equal to 2.0% of the aggregate number of Units issued pursuant to the Offering.

The closing of the Offering is expected to occur on or about February 24, 2021 (the "Closing Date") and is subject to the Company receiving all necessary regulatory approvals, including the approval of the Exchange.

The securities referred to in this press release have not been, nor will they be, registered under the U.S. Securities Act or any U.S. state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This press release does not constitute an offer for sale of securities, nor a solicitation for offers to buy any securities in the United States, nor in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

[Durim02]

Kann die neue News jemand erläutern?

[MStorm]

https://markets.ft.com/data/announce/detail?dockey=600-20210…

[Durim02]

Feb 3 (Reuters) - Sernova Corp :


* SERNOVA CORP. ANNOUNCES C$10 MILLION BOUGHT DEAL OFFERING
OF
UNITS

[keun]

!

Dieser Beitrag wurde von SelfMODus moderiert. Grund: Schreiben Sie bitte Diskussionsbeiträge ohne persönliche Angriffe bzw. ohne Beleidigungen.

[Smuudo]

!

Dieser Beitrag wurde von SelfMODus moderiert. Grund: Schreiben Sie bitte Diskussionsbeiträge zum Thema des Threads, bleiben Sie sachlich und höflich in ihrer Wortwahl.

[Ocram69]

Na ja, ganz Unrecht hat keun sicherlich nicht mit seiner Grundsatzthese. Es ist sicherlich so, dass diverse, gerade unerfahrene Anleger in Unternehmen investieren, ohne sich vorher über diese zu informieren. Darum geht es ihm, schätze ich. Wenn nämlich genau dieses Klientel zur Wort meldet kommen tatsächlich nicht selten unqualifizierte Posts.